Physician

David Redford Liljenquist, MD

According to 2025 Medicare claims, David Liljenquist, MD (NPI: 1932109931) practices endocrinology in the Idaho Falls, ID market, with the plurality of this provider's patient population coming from Bonneville, ID. This provider's primary affiliated billing organization is ROCKY MOUNTAIN DIABETES AND OSTEOPOROSIS CENTER PA (NPI: 1336220243; TIN: 82-0366217) and primary practice location at 83404-7596. Liljenquist is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), MountainStar Care Partners ACO (ACO ID: A5181), Aledade 151 Northern Territories MSSP Enhanced (ACO ID: A5349), CoreHealth Alliance LLC (ACO ID: A5645), and CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under both the MSSP and REACH models.

Liljenquist's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 844 traditional Medicare patients, billed 15,520 HCPCS/CPT codes, and received $170,783 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 23,200 prescription claims across 1,663 beneficiaries totaling $5,013,774 in drug costs, led by Ozempic (Semaglutide). DME data shows 2,300 claims. Open Payments data shows 147 records totaling $2,627,977. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $358,493 to $170,783. In contrast, Part D prescription costs have risen steadily, from $2,585,295 to $5,013,774. For DME billing, reported payments moved sharply higher in recent years, from $162,712 to $507,824.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,261	47,067	$358,493
2016	1,257	47,402	$369,858
2017	1,360	47,536	$387,846
2018	1,212	44,485	$413,491
2019	1,139	38,075	$414,253
2020	1,030	32,093	$222,966
2021	1,024	26,241	$205,451
2022	937	24,662	$225,791
2023	875	32,008	$303,129
2024	844	15,520	$170,783

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	1,143	19,631	$2,585,295
2016	1,246	20,642	$2,927,444
2017	1,284	21,893	$3,264,521
2018	1,369	22,272	$3,746,433
2019	1,433	23,499	$4,309,313
2020	1,463	23,733	$4,684,248
2021	1,519	23,965	$5,302,967
2022	1,530	23,312	$5,820,111
2023	1,585	23,406	$6,642,305
2024	1,663	23,200	$5,013,774

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	995	2,962	$191,081
2016	1,023	2,945	$159,320
2017	930	2,413	$166,453
2018	922	2,541	$244,389
2019	867	2,812	$374,688
2020	789	2,701	$376,252
2021	736	2,858	$425,154
2022	702	3,000	$453,575
2023	690	3,087	$484,823
2024	648	2,300	$528,736

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	597	832	$80
83970	Parathormone (parathyroid hormone) level	284	371	$40
84443	Blood test, thyroid stimulating hormone (tsh)	262	339	$16
83036	Hemoglobin a1c level	392	547	$9
36415	Insertion of needle into vein for collection of blood sample	624	992	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	695	25,585	$815,081
Mounjaro	Tirzepatide	653	20,366	$738,907
Trulicity	Dulaglutide	288	11,204	$364,521
Jardiance	Empagliflozin	313	17,927	$341,365
Farxiga	Dapagliflozin Propanediol	261	14,698	$268,883

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	205	987	$372,964
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	51	159	$38,191
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	28	116	$37,920
E0784	External ambulatory infusion pump, insulin	Y	14	83	$27,817
A4225	Supplies for external insulin infusion pump, syringe type cartridge, sterile, each	N	51	169	$11,847

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$1,188	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	69	$2,626,790	Dexcom, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Redford Liljenquist, MD?

Tedicare shows public-source Medicare data for David Redford Liljenquist, MD (NPI 1932109931), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Redford Liljenquist, MD have ACO affiliation data?

David Redford Liljenquist, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), MountainStar Care Partners ACO (MSSP, ACO ID A5181), Aledade 151 Northern Territories MSSP Enhanced (MSSP, ACO ID A5349), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to David Redford Liljenquist, MD?

David Redford Liljenquist, MD is linked to ROCKY MOUNTAIN DIABETES AND OSTEOPOROSIS CENTER PA (billing NPI 1336220243) in the available physician profile data.

Does David Redford Liljenquist, MD have Open Payments data?

David Redford Liljenquist, MD has 147 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.